Compare Adaptive Biotechnologies Corp (ADPT) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Corning Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $25.25 (market cap $4.04B), while Corning Incorporated trades at $167.76 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 33.9× Adaptive Biotechnologies Corp's market cap, and Corning Incorporated pays a 0.7% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GLW | |
|---|---|---|
Market Cap | $4.04B | $137.12B |
Sector | Health | Technology |
52-Week High | $25.45 | $255.79 |
52-Week Low | $12.30 | $64.52 |
Enterprise Value | $4.10B | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Corning (GLW) trades at $167.02, up 5.88% over 24 hours, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS up 30% year-over-year. Revenue growth is accelerating, driven by optical communications and AI data center demand, though valuation multiples remain elevated. Recent news highlights analyst upgrades citing improved fundamentals post-sell-off.
Outlook is positive with a consensus price target of $193.33 (15.8% upside), supported by AI infrastructure growth and profitability improvements. Risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling solar and automotive segments. Institutional sentiment is bullish with 56.75% buy ratings, but technical indicators warn of near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
